Indication: Multiple Myeloma
An Open-Label, Multicenter, Non-Randomized Phase 2 Study of PF-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One ANTI-CD38 Antibody (MM 20-84)
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Pfizer
